Vertex guns for virtual trials but hits pause, sees delays for 'some new study starts'

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.

In an update Friday, Vertex said: “For ongoing studies, Vertex is working with clinical trial sites to enable virtual clinic visits and home delivery of study drug to ensure study continuity and medical monitoring, and to facilitate study procedures.